Two Sigma Investments 13F: Adds $25M to AUPH Stake

Two Sigma Investments has significantly increased its stake in Aurinia Pharmaceuticals Inc. (NasdaqGM: AUPH). As per the latest 13F filing, Two Sigma boosted its holdings by 74.7%, adding 1,465,963 shares to its portfolio. This brings its total to 3,428,705 shares, valued at approximately $56.4 million as of the reporting period.

What Changed in Two Sigma Investments' Aurinia Pharmaceuticals Position

Two Sigma Investments made a substantial addition to its Aurinia Pharmaceuticals position, going from 1,962,742 shares to 3,428,705 shares. This increase of 1,465,963 shares represents a 74.7% uplift, reflecting a strong vote of confidence in the biotechnology company.

Other Institutional Activity in Aurinia Pharmaceuticals

TANG CAPITAL MANAGEMENT LLC also increased its stake in Aurinia Pharmaceuticals, adding 900,000 shares for a total of 12,229,500 shares worth about $181.2 million. Meanwhile, BLACKROCK, INC. slightly reduced its holdings by 82,608 shares, ending with 7,845,521 shares valued at approximately $116.3 million. NEA MANAGEMENT COMPANY, LLC maintained its position with 3,969,834 shares, valued at around $58.8 million. STATE STREET CORP added 25,107 shares, bringing its total to 2,527,099 shares, valued at $37.5 million.

Aurinia Pharmaceuticals Inc. Stock Up 0.4%

Shares of Aurinia Pharmaceuticals Inc. (NasdaqGM: AUPH) are trading at $16.46. The company boasts a market cap of $2.12 billion with a P/E ratio of 7.6. Its beta is 1.434, indicating moderate volatility. The stock's 52-week range has been between $7.29 and $16.88, with a 50-day moving average of $15.78 and a 200-day moving average of $14.58. Aurinia has a strong current ratio of 5.55 and a quick ratio of 4.95, with a debt-to-equity ratio of 12.09.

Recent Earnings

Aurinia Pharmaceuticals reported revenue of $298.3 million, with a growth rate of 24.4%. The company achieved a net margin just shy of 100%, and a return on equity of 64.98%. Earnings per share stood at $2.16. The next earnings announcement is scheduled for July 30, 2026.

Insider Buying and Selling at Aurinia Pharmaceuticals Inc.

Recent insider activity at Aurinia Pharmaceuticals included several purchases. On June 4, 2026, insiders Jeffrey Allen Bailey, Craig Johnson, Kathleen Goetz, and Tina Susan Nova each acquired 23,931 shares. CEO Kevin Tang purchased 10,000 shares at $1.65 and another 206,005 shares at $15.28 on June 2, 2026.

Analysts Set New Price Targets

Analysts have mixed views on Aurinia Pharmaceuticals. On December 3, 2025, Leerink Partners downgraded the stock to a hold with a $16 price target. Meanwhile, Jefferies upgraded it to a buy with a target of $21 on November 7, 2025. RBC Capital downgraded it to a hold with a $15 target on November 5, 2025. The consensus target price is $17 from 7 analysts.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company based in Edmonton, Canada, specializing in treatments for autoimmune diseases. It is best known for LUPKYNIS, a therapy for lupus nephritis. The company also develops aritinercept, targeting B cell-activating factors for autoimmune conditions. Led by CEO Kevin C. Tang, Aurinia operates in the biotechnology sector, employing 128 people.

Bottom Line

Two Sigma Investments' increased stake in Aurinia Pharmaceuticals is a significant move, reflecting strong confidence in the company's growth potential. Investors often track such institutional changes as they can signal broader market sentiment. However, it's important to remember that 13F filings are historical snapshots and may not represent the current position.